Should We Still use Atypicals for Alzheimer’s Disease? Carlat Reports

Should We Still use Atypicals for Alzheimer’s Disease?

The Carlat Psychiatry Report, Volume 5, Number 1, January 2007
https://www.thecarlatreport.com/newsletter-issue/tcprv5n1/

From The Carlat Psychiatry Report, January 2007, Antidepressant Round-up 2007

Issue Links: Learning Objectives | Editorial Information

Topics: Antipsychotics

David Fassler, MD

Only after thinking long and hard about it, according to the long anticipated results from the CATIE-AD trial. In this study, 421 patients with Alzheimer’s Disease were randomized to double-blind treatment with Zyprexa (mean dose, 3.2 mg/day), Seroquel (34.1 mg/day), Risperdal (0.7 mg/day), or placebo.

You can't view details of this content, please login or buy subscription here

David Fassler, MD

Clinical Professor of Psychiatry University of Vermont College of Medicine

Dr. Fassler discloses that he has no relationships with commercial entities related to the content of this educational activity.